Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2014-03-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses
NCT04980456
Daily Disposable Comparison Study
NCT02094677
Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens
NCT01151371
Comparative Clinical Evaluation of Daily Disposable Lenses in Symptomatic Lens Wearers
NCT00953407
Clinical Comparison of Two Daily Disposable Lenses Among Daily Disposable Lens Wearers
NCT01134211
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
etafilcon A lens
Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
etafilcon A
Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
nelfilcon A lens
Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
nelfilcon A
Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
filcon II 3 lens
Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
filcon II 3
Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
filcon II 3
Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
etafilcon A
Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
nelfilcon A
Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has had a self-reported visual exam in the last two years
* Is an adapted soft CL wearer
* Must be able to wear their lenses at least 3 full days, 10 hours per day, assuming there are no contraindications for doing so
* Has a CL spherical prescription between - 1.00 and - 6.00 (inclusive)
* Has less than 1.25 D spectacle cylinder in each eye.
* Baseline vision of 20/40 or better (in each eye) with their habitual vision correction or 20/20 best-corrected.
* Is correctable to at least 20/25 distance visual acuity with study contact lenses in each eye
* Has clear corneas and no active ocular disease
* Has read, understood and signed the information consent letter
* Is willing to comply with the wear schedule (at least 3 full days)
* Is willing to comply with the visit schedule
Exclusion Criteria
* Currently wears rigid gas permeable contact lenses.
* Has a history of not achieving comfortable CL wear (3 days per week; \> 8 hours/day)
* Has a CL prescription outside the range of - 1.00 to -6.00D
* Has a spectacle cylinder greater than -1.25D of cylinder in either eye.
* Has best corrected spectacle distance vision worse then 20/25 in either eye.
* Has any systemic disease affecting ocular health.
* Is using any systemic or topical medications, (includes rewetting drops, artificial tears and allergy drops), that will affect ocular health. Occasional use is acceptable but not during the trial.
* Has any ocular pathology or severe insufficiency of lacrimal secretion
* Has persistent, clinically significant corneal or conjunctival staining
* Has active neovascularization or any central corneal scars.
* Is aphakic.
* Is presbyopic.
* Has undergone corneal refractive surgery.
* Is participating in any other type of eye related clinical or research study.
18 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CooperVision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meng C Lin, OD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Berkeley
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Berkeley Clinical Research Center (UCB-CRC)
Berkeley, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EX-MKTG-46
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.